Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study.
Fabrizio NelliCarlo SignorelliAgnese FabbriDiana GiannarelliAntonella VirtuosoJulio Rodrigo Giron BerriosEleonora MarrucciCristina FioreMarta SchirripaMario Giovanni ChilelliFrancesca PrimiValentina PanichiGiuseppe TopiniMaria Assunta SilvestriEnzo Maria RuggeriPublished in: Cancers (2023)
Our data suggest expansion of NK cell counts as the most noteworthy change in circulating lymphocytes after the third dose of tozinameran in cancer patients receiving PD-1/PD-L1-targeted agents. This change correlated with enhanced therapeutic efficacy, improving the rate of disease control, and prolonging survival outcomes. Similar findings have not been previously reported, implying that they have proof-of-concept value and warrant further confirmation.